Back to search results

Early Discharge with Subcutaneous Furosemide for Acute Heart Failure

This study is looking at whether people with acute heart failure (sudden worsening of heart failure symptoms) can go home sooner if they use a special device to give themselves Lasix® ONYU (furosemide injection) under the skin. This is compared to the usual hospital care. You might be able to join if you are at least 18 years old, are in the hospital or emergency room for heart failure, and are expected to need more IV (intravenous, or into a vein) diuretics. You also need a safe home environment and be able to use the device yourself or have a caregiver who can. The main goal is to see if people in the early discharge group spend more days alive and out of the hospital within 30 days.

Study design
This is a cluster-randomized, crossover study involving 250 participants. Practice groups will switch between providing early discharge with subcutaneous furosemide and standard care.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for 30 days after discharge to measure days alive and out of the hospital.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07018297

Early Discharge With Subcutaneous Furosemide Versus Standard Care in Acute Heart Failure

Not Yet Recruiting
PHASE3Ages 18+InterventionalTreatment
University of Texas Southwestern Medical Center
~250 participants
Updated 2026-05-04 on ClinicalTrials.gov
What's tested:Early Discharge with Lasix® ONYU (furosemide injection, for subcutaneous use) using SQIN-Infusor

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Days alive and out of the hospital
Measured over 30-day

Conditions

Heart Failure
Acute Decompensated Heart Failure

Explore related trials

Heart Failure

NCT07018297

Where you'd take part

This study runs at 2 sites. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Baylor Scott and White Health System

    Dallas, Texasstudy coordinator listed

  • University of Texas Southwestern Medical Center

    Dallas, Texasno site contact published

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Who to contact

Ambarish Pandey, MD
[email protected]
214-645-2101
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Age ≥ 18 years
Within 48 hours of inpatient stay OR ED presentation for HF with plans for admission OR observation stay/short-stay hospitalization for HF
Expected to require at least 24 additional hours of IV diuretics
Adequate home environment for self-care
Patient or caregiver capable of operating subcutaneous delivery device

Exclusion

Cognitive impairment preventing informed consent
Geographic barriers to follow-up
Pregnancy or breastfeeding
IV furosemide requirement \>250mg/day
eGFR \<20 mL/min/1.73m2
Type 1 myocardial infarction during index admission
End-stage HF with receipt or consideration of heart transplant or LVAD or requiring inotropic or mechanical circulatory support
Potassium \<3.0 or \>6.0 mmol/L or sodium \<125 mmol/L

What this trial measures

  • Days alive and out of the hospital30-day

    Days alive and out of the hospital will be ascertained via retrospective review of the electronic health record.